• Explore /
  • Poster
  • / Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

Abstract Poster

Authors

Erica Stringer-Reasor

Erica Michelle Stringer-Reasor

University of Alabama at Birmingham, Birmingham, AL

Erica Michelle Stringer-Reasor , Barbara Jane O'Brien , Ariel Topletz-Erickson , Jason B White , Mina Lobbous , Kristen Riley , Jennifer Childress , Kim LaMaster , Michelle E. Melisko , Aki Morikawa , John Frederick De Groot , Ian E. Krop , Vicente Valero , Mothaffar F. Rimawi , Antonio C. Wolff , Debu Tripathy , Nancy U Lin , Rashmi Krishna Murthy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT03501979

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1044)

DOI

10.1200/JCO.2021.39.15_suppl.1044

Abstract #

1044

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Carey K. Anders

First Author: Fei Ma

First Author: Giuseppe Curigliano

First Author: Erika Paige Hamilton